Cost minimisation analysis of 12 or 24 weeks of peginterferon alfa-2b + ribavirin for hepatitis C virus

De Compadri P, Koleva D, Mangia A, Motterlini N, Garattini L

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

Indexing Status
Subject indexing assigned by CRD

MeSH
Antiviral Agents /therapeutic use; Cost-Benefit Analysis; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon Alfa-2b /therapeutic use; Ribavirin /therapeutic use

AccessionNumber
22008100379

Date bibliographic record published
30/09/2008